NCT07014943View on ClinicalTrials.gov

High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Primary Central Nervous System Lymphoma (PCNSL)
Interventions
DRUG

High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy

Gemcitabine (2.5 g/m²) (Days -9 and -3), Busulfan (3.2 mg/kg) (Days -9 to -7), and Thiotepa (5 mg/kg) (Days -5, -4, and -3) were all administered intravenously. Peripheral stem cells were infused on Day 0.

Trial Locations (1)

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER